IQVIA Holdings Inc. with ticker code (IQV) have now 20 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between 281 and 215 and has a mean target at $251.30. Given that the stocks previous close was at $220.89 and the analysts are correct then we can expect a percentage increase in value of 13.8%. It’s also worth noting that there is a 50 day moving average of $220.64 while the 200 day moving average is $210.82. The company has a market capitalization of 40.07B. The current share price for the company is: 218.82 USD
The potential market cap would be $45,587,313,079 based on the market consensus.
The company has a dividend yield of 2.93%. Other points of data to note are a P/E ratio of 37.66, revenue per share of 79.12 and a 4.79% return on assets.
IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, providing outsourced clinical research and clinical trial related services. The Contract Sales & Medical Solutions segment provides health care provider, including contract sales and patient engagement services to both biopharmaceutical clients and the broader healthcare market. The Company protects individual patient privacy. The Company conducts business in more than 100 countries.
